Literature DB >> 3865016

Interaction of cyclosporin A with antineoplastic agents.

O Kloke, R Osieka.   

Abstract

A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse. The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow. Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues. This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865016     DOI: 10.1007/bf01739677

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  4 in total

1.  Cyclosporin-associated fatal convulsions.

Authors:  T Velu; L Debusscher; P A Stryckmans
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

2.  Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults.

Authors:  D Hoelzer; E Thiel; H Löffler; H Bodenstein; L Plaumann; T Büchner; D Urbanitz; P Koch; H Heimpel; R Engelhardt
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

Review 3.  Retroviruses as etiologic agents of some animal and human leukemias and lymphomas and as tools for elucidating the molecular mechanism of leukemogenesis.

Authors:  R C Gallo; F Wong-Staal
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

4.  Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription.

Authors:  M Krönke; W J Leonard; J M Depper; S K Arya; F Wong-Staal; R C Gallo; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

  4 in total
  5 in total

1.  Enhancement of etoposide-induced cytotoxicity by cyclosporin A.

Authors:  R Osieka; S Seeber; R Pannenbäcker; D Soll; P Glatte; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 3.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

Review 4.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

5.  A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells.

Authors:  Vivian Osei Poku; Surtaj Hussain Iram
Journal:  PeerJ       Date:  2022-01-05       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.